Prof. Dr. Lucie Heinzerling, MPH

Prof. Dr. med. Lucie Heinzerling is a preeminent leader in dermato-oncology and the Director of the Skin Cancer Center at LMU Hospital in Munich. Her clinical career is defined by a highly specialized focus on advanced melanoma, Merkel cell carcinoma, and the management of complex immune-related adverse events. With a background that spans elite medical institutions in Zurich, Berlin, and Harvard, she has become a global authority on immunotherapy. Prof. Heinzerling is particularly renowned for her work in "rechallenge" strategies—investigating how intermittent chemotherapy or targeted metabolic interventions can break primary resistance to checkpoint inhibitors, offering new hope to patients who have exhausted traditional treatment lines. Her academic contributions extend far beyond traditional clinical research, as she actively integrates public health expertise and cutting-edge technology into patient care. As a leader in the "Melanoma 2. 0" initiative, she is at the forefront of implementing artificial intelligence and digital biomarkers to improve the early detection and personalized treatment of skin cancers. Her laboratory work also explores the intersection of the human microbiome and oncology, seeking to identify gut-microbiota signatures that predict how a patient will respond to therapy. Through her roles in international guideline commissions and her commitment to shared decision-making, Prof. Heinzerling continues to shape the standards of modern oncological dermatology, ensuring that high-tech scientific advancements translate directly into improved quality of life for her patients.